Probiotix Health PLC - Launch of cholesterol reducing yoghurt
Announcement provided byProBiotix Health Plc · PBX
31 May 2022
ProBiotix Health plc
("ProBiotix" or the "Company")
Launch of cholesterol reducing yoghurt
A new probiotic yoghurt Yo-Life® with LPLDL® for cholesterol reduction launched in
ProBiotix Health Plc (AQSE: PBX), a life sciences company developing clinically proven probiotic solutions to tackle chronic lifestyle diseases like high cholesterol, high blood pressure and atherslorosis, announces that its partner, Granja Pocha has launched a probiotic functional yoghurt brand, Yo-Life®, containing ProBiotix's patented cholesterol reducing Lactobacillus plantarum strain (LPLDL®), in
LPLDL® was identified for its ability to reduce cholesterol, survive in the gut and for its long shelf life, by screening over 4,000 probiotic species in a pharma-based systematic approach. LPLDL® has six publications on its mechanisms of action and three peer reviewed publications demonstrating reductions in Total Cholesterol of up to 34.6%, LDL-Cholesterol by 28.4%, and apoB (biomarker of atheroschlerosis) by 28.6%, and is protected by an extensive patent portfolio. LPLDL® was recognised as Generally Recognized As Safe ("GRAS") by an independent Expert GRAS Panel in
Granja Pocha is one of
Yo-Life®, is a science-backed innovation brand that has been developed to help reduce cardiovascular disease risk, one of the leading causes of death in
The launch follows over two and a half years of product development with Granja Pocha and manufacturing partners CSL/Sacco to ensure the addition of LPLDL® to yoghurt does not change its taste, texture, or shelf life. LPLDL® is active in milligram amounts which provides a cost advantage over stanols or sterols which typically require doses of 2gms.
The global probiotics market is forecast to reach
Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health Plc said: "This is significant Company milestone and to our knowledge, the first time a cholesterol reducing probiotic has been launched in a commercial yoghurt with a pack claim stating: "helps reduce cholesterol". The dairy industry is a highly commoditised industry and looking for innovation and functional ingredients to differientiate from competition and to maintain it's current growth trajectory. The launch of Yo-Life® containing LPLDL® will facilitate the entry to a market where volumes and sales are significantly higher than the dietary supplement industry. ProBiotix is currently working with a number of major food and beverage partners who value innovation, to extend LPLDL® into new product ranges and territories and help people around the world reduce their cholesterol levels and risk of cardiovascular disease."
For further information, please contact:
ProBiotix Health plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Peterhouse Capital Ltd (AQSE Corporate Adviser and Broker)
Tel: 020 7220 0500
Tel: 020 7469 0930
Walbrook PR Ltd
Mob: 07876 741 001
About ProBiotix - www.probiotixhealth-ir.com
ProBiotix Health was established by OptiBiotix Health Plc to develop probiotics to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. Since its creation, ProBiotix has become a global leader in microbiome modulating probiotics for use in functional foods, supplements and biotherapeutics.
Independent clinical studies have shown that ProBiotix's principal product, LPLDL®, which is protected by an extensive patent portfolio, can reduce key cardiovascular risk biomarkers: Total Cholesterol of up to 34.6%, LDL-Cholesterol by 28.4%, and apoB (biomarker of atheroschlerosis) by 28.6%. Since launching its CholBiome® products containing LPLDL® in May 2017, ProBiotix has signed over 41 agreements and its products are now commercialised in 60 countries.
LPLDL® was designated Generally Recognized As Safe ("GRAS") by an independent Expert GRAS Panel in